SEFA-1024 / NorthSea Therap - LARVOL DELTA

Study of the Efficacy and Safety of NST-1024 Versus Placebo in Subjects With Hypertriglyceridemia (clinicaltrials.gov) - P2 | N=50 | Completed | Sponsor: NorthSea Therapeutics B.V. | Recruiting ➔ Completed

Trial completion • Dyslipidemia • Hypertriglyceridemia • APOB

NorthSea Therapeutics Announces Expansion of Leadership Team with Key Industry Veteran Hires (Businesswire) - "Topline data from SEFA-1024 Phase 2a clinical trial in SHTG expected in 3Q 2025; Interim data from Orziloben Phase 2a clinical trial in IFALD expected by 1H 2026..."

P2a data • Hepatology • Severe Hypertriglyceridemia

Study of the Efficacy and Safety of NST-1024 Versus Placebo in Subjects With Hypertriglyceridemia (clinicaltrials.gov) - P2 | N=50 | Recruiting | Sponsor: NorthSea Therapeutics B.V. | Trial completion date: Feb 2024 ➔ Apr 2025 | Trial primary completion date: Feb 2024 ➔ Dec 2024

Trial completion date • Trial primary completion date • Dyslipidemia • Hypertriglyceridemia

Open-label Study to Evaluate the Effects of NST-1024 on the PK of Multiple Drugs in Healthy Subjects (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: NorthSea Therapeutics B.V. | Not yet recruiting ➔ Completed

Trial completion

Study of the Efficacy and Safety of NST-1024 Versus Placebo in Subjects With Hypertriglyceridemia (clinicaltrials.gov) - P2 | N=50 | Recruiting | Sponsor: NorthSea Therapeutics B.V. | Not yet recruiting ➔ Recruiting

Enrollment open • Dyslipidemia • Hypertriglyceridemia

Study of the Efficacy and Safety of NST-1024 Versus Placebo in Subjects With Hypertriglyceridemia (clinicaltrials.gov) - P2 | N=50 | Not yet recruiting | Sponsor: NorthSea Therapeutics B.V.

New P2 trial • Dyslipidemia • Hypertriglyceridemia • APOB • CRP

A Phase 1, First Time in Humans Study of NST-1024 (clinicaltrials.gov) - P1 | N=96 | Completed | Sponsor: NorthSea Therapeutics B.V. | Recruiting ➔ Completed | Trial completion date: Dec 2022 ➔ Jun 2022

Trial completion • Trial completion date • Dyslipidemia • Hypertriglyceridemia

Structurally-engineered fatty acid 1024 (SEFA-1024) improves diet-induced obesity, insulin resistance, and fatty liver disease. (PubMed, Lipids) - "The mechanism by which SEFA-1024 works may include increasing aGLP-1, promoting fatty acid oxidation, and inhibiting hepatic triglyceride formation. SEFA-1024 may serve as a potential treatment for obesity-related diabetes and NAFLD."

Journal • Cardiovascular • Diabetes • Genetic Disorders • Hepatology • Metabolic Disorders • Non-alcoholic Fatty Liver Disease • Obesity

Open-label Study to Evaluate the Effects of NST-1024 on the PK of Multiple Drugs in Heathy Subjects (clinicaltrials.gov) - P1 | N=21 | Not yet recruiting | Sponsor: NorthSea Therapeutics B.V.

New P1 trial

A Phase 1, First Time in Humans Study of NST-1024 (clinicaltrials.gov) - P1 | N=96 | Recruiting | Sponsor: NorthSea Therapeutics B.V. | Trial completion date: Dec 2021 ➔ Dec 2022 | Trial primary completion date: Oct 2021 ➔ Jul 2022

Trial completion date • Trial primary completion date • Dyslipidemia • Hypertriglyceridemia

A Phase 1, First Time in Humans Study of NST-1024 (clinicaltrials.gov) - P1; N=96; Recruiting; Sponsor: NorthSea Therapeutics B.V.; Trial completion date: Jun 2021 ➔ Dec 2021; Trial primary completion date: Jun 2021 ➔ Oct 2021

Clinical • Trial completion date • Trial primary completion date • Dyslipidemia • Hypertriglyceridemia

A Phase 1, First Time in Humans Study of NST-1024 (clinicaltrials.gov) - P1; N=96; Recruiting; Sponsor: NorthSea Therapeutics B.V.

Clinical • New P1 trial • Dyslipidemia • Hypertriglyceridemia